Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J's Remicade poised to dominate paediatric ulcerative colitis market

This article was originally published in Scrip

Executive Summary

Paediatric patients in Canada will become the first to have access to Remicade (infliximab) for treating moderately to severely active ulcerative colitis, following Health Canada’s approval of the drug for this indication. This decision is likely to pave the way for similar indication extensions for children in other markets.

You may also be interested in...

Extended hold on Arikace dogs Insmed and delays verdict on liposomes in CF

The FDA is continuing its clinical hold on Arikace, the clinical hold placed in August on Phase III trials of Arikace, a hotly-tipped cystic fibrosis candidate, until second species carcinogenicity data is generated. This will significantly delay the development of this keenly awaited antibiotic which is spearheading new liposomal technology.

Lucentis improves vision for DME sufferers

Encouraging Phase III results raise hopes for an additional ophthalmic indication for Lucentis. Results presented at the recent American Diabetes Association meeting reveal that Roche's Lucentis (ranibizumab) significantly improves visual acuity among patients with diabetic macular edema (DME). If approved by the FDA, this would give Lucentis a third indication within the US ophthalmic market.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts